Back to Results

Inventiva Sa (IVA)

Inventiva S.A. is a French clinical-stage biopharmaceutical company with an ADR listed on NASDAQ under the ticker IVA. The underlying business is focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and international markets. Its lead program, Lanifibranor, is a novel pan-peroxisome proliferator-activated receptor agonist being evaluated in the NATiV3 Phase 3 trial for adults with MASH. Inventiva is also advancing Odiparcil for mucopolysaccharidoses and a pre-clinical TGF-ß program for idiopathic pulmonary fibrosis. Incorporated in 2011, the company is headquartered in Daix, France.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-IVA
$2.54
-30.1% Downside
Overvalued
$15.20
318.7% Upside
Bargain
Weak
0.0%
November 23, 2026
13.5x
323.2x
890.9 M
875.4 M
14.2%
76.2%
3.5
39.1%
Valuation • Fair Value

Inventiva Sa (NASDAQ-IVA) Fair Value by Valuation Model

Review the available estimates for Inventiva Sa (NASDAQ-IVA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.54

Estimated downside of 30.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.54

Comparable-company valuation reference.

Analyst Price Target

$15.20

Analysts imply upside of 318.7%.

How to read these valuation models

Use the 4 available valuation references for Inventiva Sa (NASDAQ-IVA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Inventiva Sa (NASDAQ-IVA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

2.805 M

Current operating scale indicator.

Revenue Forecast

1.855 M

Forward revenue estimate.

EBITDA

-170.2 M

Current operating profitability reference.

EBITDA Forecast

-161.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Inventiva Sa (NASDAQ-IVA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Inventiva Sa (NASDAQ-IVA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-6.01

No elevated caution signal from this screen.

Altman Z-Score

3.5

Relatively strong balance-sheet zone.

FCF / Net Income

39.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Inventiva Sa (NASDAQ-IVA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Inventiva Sa (NASDAQ-IVA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 23, 2026

Days to Earnings

17

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Inventiva Sa (NASDAQ-IVA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Inventiva Sa (NASDAQ-IVA) Stock Forecast & Technical Outlook

Review Inventiva Sa (NASDAQ-IVA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Inventiva Sa (NASDAQ-IVA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Inventiva Sa (NASDAQ-IVA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Inventiva Sa (NASDAQ-IVA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Inventiva Sa (NASDAQ-IVA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Inventiva Sa (NASDAQ-IVA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Inventiva Sa (NASDAQ-IVA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Inventiva Sa (NASDAQ-IVA) has a Strong Buy consensus, with 11 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 11
Hold 0
Sell 0
FAQ • Fast Investor Answers

Inventiva Sa (NASDAQ-IVA) Stock FAQ

Data-supported answers about Inventiva Sa (NASDAQ-IVA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.54
Estimated downside 30.1%
Valuation Rating
Overvalued
Estimated downside of 30.1%
Analyst Target
$15.20
Implied upside 318.7%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Inventiva Sa (NASDAQ-IVA) is $2.54. This implies an estimated downside of 30.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 30.1% versus the current market price.

The available analyst price target for Inventiva Sa (NASDAQ-IVA) is $15.20. The analyst target implies estimated upside of 318.7%.

The current financial health read for Inventiva Sa (NASDAQ-IVA) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Inventiva Sa (NASDAQ-IVA) is November 23, 2026.

The latest available data indicates no current dividend yield for Inventiva Sa (NASDAQ-IVA).

The current market capitalization listed for Inventiva Sa is 890.9 M.

The current enterprise value listed for Inventiva Sa is 875.4 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Inventiva Sa is NASDAQ-IVA, and the stock is listed on NASDAQ.

Inventiva Sa (NASDAQ-IVA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Inventiva Sa is 14.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Inventiva Sa is 76.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B